Aarti Pharmalabs Secures Spot Among Top 3 Global Producers as Xanthine Capacity Reaches 9,600 TPA

Synopsis: Aarti Pharmalabs Limited has inaugurated a new state-of-the-art manufacturing block at its Tarapur Unit 5 facility in Maharashtra. The expansion adds 3,600 TPA of Xanthine derivative manufacturing capacity, increasing the company’s total installed capacity to 9,600 TPA and positioning it among the top three Xanthine derivative manufacturers globally.

This expansion alters the global competitive landscape, instantly securing Aarti Pharmalabs a spot among the top three global producers of xanthine derivatives. Aarti Pharmalabs Limited is currently trading at Rs 699.9. The stock opened at Rs 684.95, reached a day high of Rs 701, and has so far recorded a day’s low of Rs 683.85. The current market capitalisation of the company is Rs 6,326 crore, and it is trading at a p/e ratio of 35.8, which is slightly higher than the industry peer median of 34.86

Xanthine derivatives are pharmaceutical ingredients that are widely used in respiratory medicines, nutraceuticals and other therapeutic applications. Aarti Pharmalabs has a larger manufacturing capacity to meet the growing demand of the global market. It can cater to bigger customers; economies of scale will improve, and its position in the global supply chain of pharmaceuticals will improve.

The company has also commissioned another manufacturing block at Tarapur Unit 5, Maharashtra, after obtaining all the regulatory approvals. The facility adds 3,600 TPA capacity for the Xanthine derivative, taking the company’s total capacity to 9,600 TPA. Trial production is already underway, and management expects to ramp the plant gradually up to optimal utilisation in the coming quarters.

The acquisition provides a significant boost to the manufacturing capacity of Aarti Pharmalabs and enables it to cater to larger customers across the globe and support future revenue growth. The company enhances its competitive position in a niche pharmaceutical segment by becoming one of the three largest producers of xanthine derivatives in the world. The phased ramp-up of the facility also provides higher capacity utilisation and operating leverage as production ramps up over the next few quarters.

Financials

Revenue from operations stood at Rs 583 crore in Q4 FY26 compared to Rs 564 crore in Q4 FY25, a modest growth of 3.37 percent year-on-year, the company said. However, operating profit fell from Rs 146 crore to Rs 113 crore, while operating margin contracted from 26 percent to 19 percent, indicating pressure on profitability despite higher revenue.

Net profit fell to Rs 61 crore in Q4 FY26 from Rs 88 crore in Q4 FY25, down 30.7 percent YoY. Earnings per share (EPS) also declined from Rs 9.75 to Rs 6.74 indicating lower earnings available to shareholders during the period.

In terms of return ratios, the company reported a ROCE of 10.7 percent and ROE of 8.59 percent, reflecting moderate returns on capital and shareholders’ equity. The debt-to-equity ratio stood at 0.36x, indicating a comfortable leverage position. While debtor days increased from 99 to 117 days and inventory days rose sharply from 190 to 280 days, working capital days improved to 90 days from 105 days, supported by an increase in payable days from 90 to 146 days.

Aarti Pharmalabs Limited is a leading Indian pharmaceutical and nutraceutical manufacturing company with a global footprint. The company offers CDMO/CMO services for small molecule drug substances, produces generic APIs, intermediates, HPAPIs, corticosteroids, cytotoxic and oncology products and is a world leader in the production of Xanthine derivatives serving innovator pharmaceutical companies at clinical and commercial stages.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.inare their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Aarti Pharmalabs Secures Spot Among Top 3 Global Producers as Xanthine Capacity Reaches 9,600 TPA appeared first on Trade Brains.